STING1 and melanoma: Collectively, these results indicate that although melanoma-intrinsic STING activity can mediate antitumor immune responses at the early stages of tumor growth (1–2 weeks), it is insufficient to mediate long-lasting tumor control in response to treatment with a STING agonist.